RxDoctor Payments Data

Susan Rushing, NP

Family · Columbus, MSNPI 1912539362

Payments from drug & device makers

$748in general payments, 2019–2025

Across 31 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$281
  • BD$269
  • AstraZeneca$107
  • Lilly USA, LLC$40
  • Boston Scientific$36
  • Exact Sciences$15

What the payments were for

  • Food & beverage$748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk9$281
BD10$269
AstraZeneca7$107
Lilly USA, LLC2$40
Boston Scientific2$36
Exact Sciences1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$748 in reported general payments places this provider in the 60th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$117,585
Medicare patients
383
Services billed
5,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$55,305
EliquisApixaban13$11,749
JanuviaSitagliptin Phosphate12$11,406
Tresiba Flextouch U-100Insulin Degludec13$6,285
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,804
Metformin Hcl ErMetformin Hcl74$1,442
Albuterol Sulfate HfaAlbuterol Sulfate52$1,298
Atorvastatin Calcium155$1,268
Potassium Chloride57$1,103
Gabapentin102$1,097
Diclofenac Sodium20$1,092
Doxycycline Hyclate142$1,074
Metoprolol Succinate76$1,073
Levothyroxine Sodium140$995
Omeprazole129$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$281$55,30544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,007 family providers in Mississippi.

Other family in Columbus

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →